Computational approach to annotating variants of unknown significance in clinical next generation sequencing

Lab Medicine

Volumn 46, Issue 4, 2015, Pages 285-289

  Schulz, Wade L ^a   Tormey, Christopher A ^a,b   Torres, Richard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN P53; UNCLASSIFIED DRUG; V KIT HARDY ZUCKERMAN 4; VIRUS PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ALGORITHM; GENE MUTATION; GENETIC CONSERVATION; GENETIC VARIABILITY; GRANTHAM SCORE; HUMAN; NEXT GENERATION SEQUENCING; POLYPHEN 2; PREDICTION; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN ANALYSIS THROUGH EVOLUTIONARY RELATIONSHIPS; REVIEW; SORTING INTOLERANT FROM TOLERANT; BIOLOGY; DNA SEQUENCE; HIGH THROUGHPUT SEQUENCING; MOLECULAR GENETICS;

ALGORITHMS; COMPUTATIONAL BIOLOGY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR SEQUENCE ANNOTATION; SEQUENCE ANALYSIS, DNA;

EID: 84949750725     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMWZH57BRWOPR5RQ     Document Type: Review

References (20)

1. Peterson TA, Doughty E, Kann MG. Towards precision medicine: advances in computational approaches for the analysis of human variants. J Mol Biol. 2013;425(21):4047-4063.
2. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. Genome Res. 2009;19(9):1553-1561.
3. Pabinger S, Dander A, Fischer M, et al. A survey of tools for variant analysis of next-generation genome sequencing data. Brief Bioinform. 2014;15(2):256-278.
4. Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB, IARC Unclassified Genetic Variants Working Group. In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat. 2008;29(11):1327-1336.
5. Grantham R. Amino acid difference formula to help explain protein evolution. Science. 1974;185(4154):862-864.
6. Marini NJ, Thomas PD, Rine J. The use of orthologous sequences to predict the impact of amino acid substitutions on protein function. PLoS Genet. 2010;6(5):e1000968. doi: 10.1371/journal.pgen.1000968.
7. Ng P, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812-33814.
8. Thomas PD, Campbell MJ, Kejariwal A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003;13(9):2129-2141.
9. Dorfman R, Nalpathamkalam T, Taylor C, et al. Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene? Clin Genet. 2010;77(5):464-473.
10. Brunham LR, Singaraja RR, Pape TD, Kejariwal A, Thomas PD, Hayden MR. Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene. PLoS Genet. 2005;1(6):e83.
11. Chang X, Wang K. wANNOVAR: annotating genetic variants for personal genomes via the web. J Med Genet. 2012;49(7):433-436.
12. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11(5):863-874.
13. Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, Thomas PD. PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res. 2010;38(Database issue):D204-210.
14. Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet. 2001;10(6):591-597.
15. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
16. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013:313-318.
17. Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009;106(5):1542-1547.
18. Döhner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program. 2011;2011:36-42.
19. Martelli MP, Sportoletti P, Tiacci E, Martelli MF, Falini B. Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev. 2013;27(1):13-22.
20. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12(9):599-612